L-γ-glutamyl-L-γ-glutamyl-L-γ-glutamyl-L-γ-glutamyl-L-γ-glutamyl-L-glutamic acid heptakis-t-butyl ester | 118252-57-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-γ-glutamyl-L-γ-glutamyl-L-γ-glutamyl-L-γ-glutamyl-L-γ-glutamyl-L-glutamic acid heptakis-t-butyl ester
• 英文别名: H-gGlu(OtBu)-gGlu(OtBu)-gGlu(OtBu)-gGlu(OtBu)-gGlu(OtBu)-Glu(OtBu)-OtBu；ditert-butyl (2S)-2-[[(4S)-4-[[(4S)-4-[[(4S)-4-[[(4S)-4-[[(4S)-4-amino-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]amino]pentanedioate
• CAS: 118252-57-6
• 化学式: C₅₈H₁₀₀N₆O₁₉
• 分子量: 1185.46
• InChiKey: SGHJJFDYWFNQER-BGBFCPIGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  83
• 可旋转键数：
  43
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  356
• 氢给体数：
  6
• 氢受体数：
  20

反应信息

• 作为反应物：
  描述：

  L-γ-glutamyl-L-γ-glutamyl-L-γ-glutamyl-L-γ-glutamyl-L-γ-glutamyl-L-glutamic acid heptakis-t-butyl ester 、 5--N-methylamino>thenoic acid 在 diethyl cyanophosphoridate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以44%的产率得到ditert-butyl (2S)-2-[[(4S)-4-[[(4S)-4-[[(4S)-4-[[(4S)-4-[[(4S)-4-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]amino]pentanedioate
  参考文献：
  名称：

  Syntheses and thymidylate synthase inhibitory activity of the poly-.gamma.-glutamyl conjugates of N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ICI D1694) and other quinazoline antifolates

  摘要：

  Thirteen poly-gamma-glutamates derived from several novel antifolates have been synthesized by a convergent route. The syntheses of poly-gamma-glutamyl conjugates of N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (8) (ICI D1694), 2-desamino-N10-propargyl-5,8-dideazafolic acid (6), 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (7), 2-desamino-2-methyl-N10-propargyl-2'-fluoro-5,8-dideazafolic acid (9), and 2-desamino-2-methyl-4-chloro-N10-propargyl-2'-fluoro-3,5,8-trideazafolic acid (11) are described. A key step in the route involves coupling of an alpha-tert-butyl-protected poly-gamma-glutamate of the required chain length to the appropriate 5,8-dideazapteroic acid, obtained by carboxypeptidase G2 cleavage of the parent monoglutamate, if available, or by chemical synthesis. Deprotection with trifluoroacetic acid in the final step gave the desired poly-gamma-glutamyl antifolates as their trifluoroacetate salts. As inhibitors of thymidylate synthase, these polyglutamates were more potent in every case than the corresponding non-polyglutamylated drug.

  DOI：

  10.1021/jm00083a008
• 作为产物：
  描述：

  Z-谷安酸叔丁基酯 在 palladium 10% on activated carbon 、 氢气 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 154.5h， 生成 L-γ-glutamyl-L-γ-glutamyl-L-γ-glutamyl-L-γ-glutamyl-L-γ-glutamyl-L-glutamic acid heptakis-t-butyl ester
  参考文献：
  名称：

  [EN] PROCESSES OF PREPARING POLYGLUTAMATED ANTIFOLATES AND USES OF THEIR COMPOSITIONS
  [FR] PROCÉDÉS DE PRÉPARATION D'ANTIFOLATES POLYGLUTAMIQUES ET LEURS UTILISATIONS

  摘要：

  本文提供了制备多聚谷氨酸化合物的方法，例如多聚谷氨酸化抗叶酸类化合物，以及包含这些化合物的药物组合物，还提供了基本纯净的多聚谷氨酸化合物，或其药用可接受盐，或包含这些化合物的药物组合物。本公开还提供了使用多聚谷氨酸化合物和组合物治疗疾病的方法，包括高增殖性疾病如癌症，免疫系统紊乱如类风湿性关节炎，以及传染病如艾滋病、疟疾和血吸虫病。

  公开号：

  WO2021026310A1

文献信息

• Synthesis of the penta-glutamyl derivative of<i>N</i>-[4-[<i>N</i>-[3-(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)-propyl]amino]benzoyl]-L-glutamic acid (5-DACTHF). An acyclic analogue of tetrahydrofolic acid
  作者：Virgil L. Styles、James L. Kelley

  DOI：10.1002/jhet.5570270654

  日期：1990.9

  N-[4-[N-[3-(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propyl]amino]-benzoyl)-L-glutamic acid (1, 5-DACTHF, 543U76) was synthesized by a convergent route. L-γ-Glutamyl-L-γ-glutamyl-L-γ-glutamyl-L-γ-glutamyl-L-γ-glutamyl-L-glutamic acid heptakis t-butyl ester (20) was prepared in ten steps from L-glutamic acid di-t-butyl ester and N-(benzyloxycarbonyl)-L-glutamic acid α-t-butyl ester. 4-[N-[3-(2,4-Diamino-1

  N- [4- [ N- [3-（2,4-二氨基-1,6-二氢-6-氧代-5-嘧啶基）丙基]氨基]-苯甲酰基）-L-谷氨酸的五谷氨酰基衍生物（1，5-DACTHF，543U76）通过会聚路线合成。L-γ-谷氨酰基-L-γ-谷氨酰基-L-γ-谷氨酰基-L-γ-谷氨酰基-L-γ-谷氨酰基-L-谷氨酸庚基叔丁基酯（20）由L-经十个步骤制备谷氨酸二吨丁基酯和ñ - （苄氧羰基）-L-谷氨酸α -叔丁基酯。由嘧啶基丙醛3合成的4- [ N- [3-（2,4-二氨基-1,6-二氢-6-氧代-5-嘧啶基）丙基]三氟乙酰胺基]苯甲酸（6）分三步，与20缩合，然后脱保护得到N- [4- [ N- [3-（2,4-二氨基-1,6-二氢-6-氧代-5-嘧啶基）丙基]氨基]苯甲酰基]-L-γ-谷氨酰基-L-γ-谷氨酰基-L-γ-谷氨酰基-L-γ-谷氨酰基-L-γ-谷氨酰基-L-谷氨酸（2）。六谷氨酸盐2是有效的甘氨酰胺核糖核苷酸转化酶抑制剂。
• STYLES, VIRGIL L.;KELLEY, JAMES L., J. HETEROCYCL. CHEM., 27,(1990) N, C. 1809-1813
  作者：STYLES, VIRGIL L.、KELLEY, JAMES L.

  DOI：——

  日期：——
• US4880812A
  申请人：——

  公开号：US4880812A

  公开（公告）日：1989-11-14
• US4940713A
  申请人：——

  公开号：US4940713A

  公开（公告）日：1990-07-10
• [EN] PROCESSES OF PREPARING POLYGLUTAMATED ANTIFOLATES AND USES OF THEIR COMPOSITIONS<br/>[FR] PROCÉDÉS DE PRÉPARATION D'ANTIFOLATES POLYGLUTAMIQUES ET LEURS UTILISATIONS
  申请人：L E A F HOLDINGS GROUP LLC

  公开号：WO2021026310A1

  公开（公告）日：2021-02-11

  Provided herein are methods of preparing polyglutamated compounds, such as polyglutamated antifolates, and/or pharmaceutical compositions such as liposomal compositions comprising the same, Also provided herein are substantially pure polyglutamated compounds, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition such as liposomal composition comprising the same. The present disclosure further provides methods of using the polyglutamated compounds and compositions to treat diseases including hyperproliferative diseases such as cancer, disorders of the immune system such as rheumatoid arthritis, and infectious diseases such as HIV, malaria, and schistomiasis.

  本文提供了制备多聚谷氨酸化合物的方法，例如多聚谷氨酸化抗叶酸类化合物，以及包含这些化合物的药物组合物，还提供了基本纯净的多聚谷氨酸化合物，或其药用可接受盐，或包含这些化合物的药物组合物。本公开还提供了使用多聚谷氨酸化合物和组合物治疗疾病的方法，包括高增殖性疾病如癌症，免疫系统紊乱如类风湿性关节炎，以及传染病如艾滋病、疟疾和血吸虫病。